Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes?
Tóm tắt
Evidence is reviewed which suggests a linkage may exist between certain forms of de novo or acquired drug resistance and metastasis. This includes finding that expression of certain dominantly acting mutant oncogenes or tumor suppressor genes, e.g. genes which normally act to “drive” tumor progression and metastasis, can also affect the expression of drug resistance. Moreover, this can be accompanied by altered expression of certain cellular genes thought to be involved in expression of drug resistance. A direct linkage between acquired drug resistance and metastasis would suggest that tumor sublines selected for drug resistance should manifest more aggressive malignant properties than their drug‐sensitive counterparts. While this does not appear to be true for drug resistant sublines selected in vitro, indeed such cell lines frequently manifest diminished in vivo tumorigenic and/or metastatic competence, there is some evidence to support such a correlation exists for tumor cell lines that are selected in vivo for drug resistance. Attention is also drawn to the fact that new linkages between metastasis and drug resistance may be uncovered by analyzing the ability of tumor subpopulations to acquire drug resistance after one or several previous exposures to chemotherapeutic drugs, as opposed to examining intrinsic drug resistance only. Furthermore, ability to detect induced or acquired drug resistance in vitro may be strongly influenced by the types of assay used to detect and monitor drug resistanc. In particular, three‐dimensional cell culture systems may reveal acquired or induced “multicellular” drug resistance in situations where conventional two‐dimensional culture systems may therefore reveal as yet undiscovered associations between the phenotypes of metastasis and drug resistance.
Từ khóa
Tài liệu tham khảo
Biedlier JL, 1975, Membrane‐mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells, J. Natl Cancer Inst, 55, 671, 10.1093/jnci/55.3.671
Boyle JO, 1993, The incidence of p53 mutations increases with progression of head and neck cancer, Cancer Res, 53, 4477
Bradley G, 1988, Mechanism of multidrug resistance, Bioch Biophys Acta, 948, 87
Cadman EC, 1989, Resistance to Antineoplastic Agents, 168
Eastman A, 1990, Activation of programmed cell death by anticancer agents: Cisplatin as a model system, Cancer Cells, 2, 275
Fisher TC, 1993, bel‐2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways, Cancer Res, 53, 3321
Frost P, 1987, Selection of metastatic variants from a non‐metastatic murine tumor after treatment wih 2′deoxy‐5‐azacytidine or hydroxyurea: Implications for the mechanisms of tumor progression, Cancer Res, 47, 2690
Ganapathi R, 1987, Characterization in vitro and in vivo of progressively adriamycin‐resistant B16, BL6 mouse melanoma cells, Cancer Res, 37, 3464
Giavazzi R, 1983, Metastatic behavior of an adriamycin‐resistant murine tumor, Cancer Res, 43, 5081
GrahamCH KobayashiH StankiewiczKS ManS KapitainSJ KerbelRS(in press): Rapid acquisition of ‘multicellular’ drug resistance after a singular transient exposure of mammary tumor cells to alkylating agents.J Natl Canc Inst.
Hanania N, 1991, Oncogene and MDRI gene expression in rat rhabdomyosarcoma sublines of different metastatic potential, Anticancer Res, 11, 473
Isonishi S, 1991, Expression of the c‐Ha‐ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin, Cancer Res, 51, 5903
Kamesaki S, 1993, Bel‐2 protein inhibits etoposide induced apoptosis through its effects on events subsequent to topoisomerase II‐induced DNA strand breaks and their repair, Cancer Res, 53, 4251
Kerbel RS, 1988, Clonal dominance of primary tumors by metastatic cells: genetic analysis and biological implications, Cancer Surveys, 7, 597
Kerbel RS, 1989, New insights into the eovlutionary growth of tumors revealed by Southern gel analysis of tumors genetically tagged with plasmid or proviral DNA insertions, J Cell Sci, 94, 381, 10.1242/jcs.94.3.381a
Kerbel RS, 1992, Drug Resistance in Oncology, 583
Lassam NJ, 1993, Overexpression of p53 is a late event in the development of malignant melanoma, Cancer Res, 53, 2235
Mazars R, 1991, p53 mutations in ovarian cancer: a late event?, Oncogene, 6, 1685
Pauwels‐Vergely C, 1988, Chlorozotocin induced selection of autocrine and multidrug resistant variants from a rat rhabdomyosarcoma, Anticancer Res, 8, 132
Perez RP, 1993, Transformation of rat ovarian epithelial and rat‐1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity, Cancer Res, 53, 3771
Poupon MF, 1984, Amplified pulmonary metastases of a rat rhabdomyosarcoma in response to nitrosourea treatment, Cancer Treat Rep, 68, 749
Sircar S, 1987, Isolation of variants resistant to methylglyoxal bis(guanylhydrazone) from adenovirus‐transformed rat cells, Cancer Res, 47, 1339
Sklar MD, 1988, Increased resistance to cis‐diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes, Cancer Res, 48, 793
Starling JJ, 1990, In vivo selection of human tumor cells resistant to monoclonal antibody‐vinca alkaloid immunoconjugates, Cancer Res, 50, 7634
Su Z‐Z, 1993, Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha‐ras‐transformed cloned rat embryo fibroblast cells, Oncogene, 8, 1211
Teicher BA, 1993, Drug Resistance in Oncology, 263
Waghorne C, 1988, Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations, Cancer Res, 48, 6109
Walton MI, 1993, Constitutive expression of human Bcl‐2 modulates nitrogen mustard and campthothecin induced apoptosis, Cancer Res, 53, 1853
Zastawny RL, 1993, The core promoter region of the P‐glycoprotein gene is sufficient to confer differential responsiveness to wild‐type and mutant p53, Oncogene, 8, 1529